Initial therapy with pembrolizumab may result in comparable overall survival as standard chemotherapy in patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.
The median duration of response to olaparib in these patients with metastatic pancreatic cancer was more than 2 years.
Cancer drugs approved with a breakthrough therapy designation may be more or equally likely to demonstrate high clinical benefit compared with non-breakthrough therapy drugs.
The VISNU-1 trial is “the first study performed in a population selected by baseline [circulating tumor cell] count,” according to lead study author Javier Sastre, MD, PhD.
A significantly greater proportion of patients in the flumatinib group had a complete molecular response at 12 months compared with in the imatinib group.
Pembrolizumab improved PFS in this high-risk patient population, but a randomized controlled trial is warranted.
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Investigators estimated the effects of immunosuppression on poor outcomes in multiple cutaneous squamous cell carcinoma.
Researchers say they can distinguish between lesions that are benign and those that could become invasive — but the technology required is not yet used routinely.
